203 related articles for article (PubMed ID: 30767706)
1. Effects of genetic variability on rifampicin and isoniazid pharmacokinetics in South African patients with recurrent tuberculosis.
Naidoo A; Chirehwa M; Ramsuran V; McIlleron H; Naidoo K; Yende-Zuma N; Singh R; Ncgapu S; Adamson J; Govender K; Denti P; Padayatchi N
Pharmacogenomics; 2019 Mar; 20(4):225-240. PubMed ID: 30767706
[TBL] [Abstract][Full Text] [Related]
2. Effect of Genetic Variation of
Dompreh A; Tang X; Zhou J; Yang H; Topletz A; Adu Ahwireng E; Antwi S; Enimil A; Langaee T; Peloquin CA; Court MH; Kwara A
Antimicrob Agents Chemother; 2018 Mar; 62(3):. PubMed ID: 29263072
[TBL] [Abstract][Full Text] [Related]
3. Genetic and clinical predictors of rifapentine and isoniazid pharmacokinetics in paediatrics with tuberculosis infection.
Phaisal W; Albitar O; Chariyavilaskul P; Jantarabenjakul W; Wacharachaisurapol N; Ghadzi SMS; Zainal H; Harun SN
J Antimicrob Chemother; 2024 Jun; 79(6):1270-1278. PubMed ID: 38661209
[TBL] [Abstract][Full Text] [Related]
4. Effect of genetic variation in UGT1A and ABCB1 on moxifloxacin pharmacokinetics in South African patients with tuberculosis.
Naidoo A; Ramsuran V; Chirehwa M; Denti P; McIlleron H; Naidoo K; Yende-Zuma N; Singh R; Ngcapu S; Chaudhry M; Pepper MS; Padayatchi N
Pharmacogenomics; 2018 Jan; 19(1):17-29. PubMed ID: 29210323
[TBL] [Abstract][Full Text] [Related]
5. Population pharmacokinetics of rifampicin, pyrazinamide and isoniazid in children with tuberculosis: in silico evaluation of currently recommended doses.
Zvada SP; Denti P; Donald PR; Schaaf HS; Thee S; Seddon JA; Seifart HI; Smith PJ; McIlleron HM; Simonsson US
J Antimicrob Chemother; 2014 May; 69(5):1339-49. PubMed ID: 24486870
[TBL] [Abstract][Full Text] [Related]
6. Full-gene sequencing analysis of NAT2 and its relationship with isoniazid pharmacokinetics in Venezuelan children with tuberculosis.
Verhagen LM; Coenen MJ; López D; García JF; de Waard JH; Schijvenaars MM; Hermans PW; Aarnoutse RE
Pharmacogenomics; 2014 Feb; 15(3):285-96. PubMed ID: 24533708
[TBL] [Abstract][Full Text] [Related]
7. Variability in plasma rifampicin concentrations and role of
Sileshi T; Makonnen E; Telele NF; Barclay V; Zumla A; Aklillu E
Infect Dis (Lond); 2024 Apr; 56(4):308-319. PubMed ID: 38315168
[TBL] [Abstract][Full Text] [Related]
8. Influence of N-acetyltransferase 2 (NAT2) genotype/single nucleotide polymorphisms on clearance of isoniazid in tuberculosis patients: a systematic review of population pharmacokinetic models.
Thomas L; Raju AP; Chaithra ; M SS; Varma M; Saravu K; Banerjee M; Sv CS; Mallayasamy S; Rao M
Eur J Clin Pharmacol; 2022 Oct; 78(10):1535-1553. PubMed ID: 35852584
[TBL] [Abstract][Full Text] [Related]
9. Efficacy, safety, and pharmacokinetics of isoniazid affected by NAT2 polymorphisms in patients with tuberculosis: A systematic review.
Surarak T; Chumnumwat S; Nosoongnoen W; Tragulpiankit P
Clin Transl Sci; 2024 Apr; 17(4):e13795. PubMed ID: 38629592
[TBL] [Abstract][Full Text] [Related]
10. The Influence of Pharmacogenetic Variants in HIV/Tuberculosis Coinfected Patients in Uganda in the SOUTH Study.
Calcagno A; Cusato J; Sekaggya-Wiltshire C; von Braun A; Motta I; Turyasingura G; Castelnuovo B; Fehr J; Di Perri G; Lamorde M
Clin Pharmacol Ther; 2019 Aug; 106(2):450-457. PubMed ID: 30779340
[TBL] [Abstract][Full Text] [Related]
11. Pharmacogenetic Study of Drugs Affecting Mycobacterium tuberculosis.
Shabani S; Farnia P; Ghanavi J; Velayati AA; Farnia P
Int J Mycobacteriol; 2024 Apr; 13(2):206-212. PubMed ID: 38916393
[TBL] [Abstract][Full Text] [Related]
12. Population pharmacokinetics of isoniazid and dose recommendations in Mexican patients with tuberculosis.
Huerta-García AP; Medellín-Garibay SE; Ortiz-Álvarez A; Magaña-Aquino M; Rodríguez-Pinal CJ; Portales-Pérez DP; Romano-Moreno S; Milán-Segovia RDC
Int J Clin Pharm; 2020 Aug; 42(4):1217-1226. PubMed ID: 32638292
[TBL] [Abstract][Full Text] [Related]
13.
Mthiyane T; Millard J; Adamson J; Balakrishna Y; Connolly C; Owen A; Rustomjee R; Dheda K; McIlleron H; Pym AS
Antimicrob Agents Chemother; 2020 Mar; 64(4):. PubMed ID: 31964788
[TBL] [Abstract][Full Text] [Related]
14. A population approach of rifampicin pharmacogenetics and pharmacokinetics in Mexican patients with tuberculosis.
Medellin-Garibay SE; Huerta-García AP; Rodríguez-Báez AS; Magaña-Aquino M; Ortiz-Álvarez A; Portales-Pérez DP; Milán-Segovia RDC; Romano-Moreno S
Tuberculosis (Edinb); 2020 Sep; 124():101982. PubMed ID: 32810723
[TBL] [Abstract][Full Text] [Related]
15. NAT2 genotype guided regimen reduces isoniazid-induced liver injury and early treatment failure in the 6-month four-drug standard treatment of tuberculosis: a randomized controlled trial for pharmacogenetics-based therapy.
Azuma J; Ohno M; Kubota R; Yokota S; Nagai T; Tsuyuguchi K; Okuda Y; Takashima T; Kamimura S; Fujio Y; Kawase I;
Eur J Clin Pharmacol; 2013 May; 69(5):1091-101. PubMed ID: 23150149
[TBL] [Abstract][Full Text] [Related]
16. Development of a limited sampling strategy for the estimation of isoniazid exposure considering N-acetyltransferase 2 genotypes in Korean patients with tuberculosis.
Lee J; Choi G; Yang S; Ha JE; Kim ES; Park JS; Lee K; Song J; Lee JH; Lee JI
Tuberculosis (Edinb); 2021 Mar; 127():102052. PubMed ID: 33548864
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of thrice-weekly rifampicin, isoniazid and pyrazinamide in adult tuberculosis patients in India.
Hemanth Kumar AK; Kannan T; Chandrasekaran V; Sudha V; Vijayakumar A; Ramesh K; Lavanya J; Swaminathan S; Ramachandran G
Int J Tuberc Lung Dis; 2016 Sep; 20(9):1236-41. PubMed ID: 27510252
[TBL] [Abstract][Full Text] [Related]
18. Isoniazid Population Pharmacokinetics and Dose Recommendation for Korean Patients With Tuberculosis Based on Target Attainment Analysis.
Cho YS; Jang TW; Kim HJ; Oh JY; Lee HK; Park HK; Ghim JL; Long NP; Park Y; Choi YK; Phuong NTT; Shin JG;
J Clin Pharmacol; 2021 Dec; 61(12):1567-1578. PubMed ID: 34157153
[TBL] [Abstract][Full Text] [Related]
19. Correlation of N-acetyltransferase 2 genotype and acetylation status with plasma isoniazid concentration and its metabolic ratio in ethiopian tuberculosis patients.
Sileshi T; Telele NF; Burkley V; Makonnen E; Aklillu E
Sci Rep; 2023 Jul; 13(1):11438. PubMed ID: 37454203
[TBL] [Abstract][Full Text] [Related]
20. Anthropometric and Genetic Factors Associated With the Exposure of Rifampicin and Isoniazid in Mexican Patients With Tuberculosis.
Huerta-García AP; Medellín-Garibay SE; Salazar-González RA; Ortiz-Álvarez A; Magaña-Aquino M; Rodríguez-Pinal CJ; Portales-Pérez DP; Romano-Moreno S; Milán-Segovia RDC
Ther Drug Monit; 2019 Oct; 41(5):648-656. PubMed ID: 30939588
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
